Hepatorenal Syndrome: Are We Missing Some Prognostic Factors?
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Hepatorenal syndrome (HRS) is the functional renal failure associated with advanced cirrhosis and has also been described in fulminant hepatic failure. Without liver transplantation its prognosis is dismal. Our study included patients with type 1 HRS associated with cirrhosis, who were not liver transplant candidates.
To identify variables associated with improved survival.
Sixty-eight patients fulfilled the revised Ascites Club Criteria for type 1 HRS. None of them was suitable for liver transplantation. All the patients were treated with combinations of: albumin, midodrine and octreotide, pressors, and hemodialysis.
Median survival was 13 days for the whole group. Survival varied with the end-stage liver disease (ESLD) etiology: autoimmune, 49 days, cardiac cirrhosis, 22 days, idiopathic, 15.5 days, viral, 15 days, hepatitis C and alcohol, 14.5 days, alcohol 8 days, and neoplasia 4 days (p = 0.048). Survival of HRS associated with alcoholic liver disease versus other etiologies was not statistically significant (p = 0.1). Increased serum creatinine (p = 0.02) and urinary sodium 6–10 mEq/l (p = 0.027) at the initiation of therapy were prognostic factors for mortality. HRS treatment modalities (p = 0.73), use of dialysis (p = 0.56), dialysis modality (p = 0.35), use of vasopressors (p = 0.26), pre-existing renal disease (p = 0.49), gender (p = 0.90), and age (p = 0.57) were not associated with survival.
We report for the first time ESLD etiology as a prognostic factor for survival. The renal function (expressed as serum creatinine) and urinary Na (<5 mEq/l) at the time of diagnosis were found to be associated with survival, suggesting that early treatment might increase survival.
- Salerno F, Gerbes A, Ginés P, Wong F, Arroyo V. Diagnosis prevention and treatment of the hepatorenal syndrome in cirrhosis: a consensus workshop of the international ascites club. Gut. 2007;56:1310–1318.
- Runyon B. Management of adult patients with ascites due to cirrhosis. Hepatology. 2009;49:2087–2107. CrossRef
- Gines A, Escorsell A, Gines P, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology. 1993;105:229–236.
- Arroyo V, Gines P, Gerbes AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Int Ascites Club Hepatol. 1996;23:164–176.
- Gines P, Guevara M, Arroyo V, Rodes J. Hepatorenal syndrome. Lancet. 2003;362:1819–1827. CrossRef
- Wadei HM, Mai ML, Ahsan N, Gonwa TA. Hepatorenal syndrome: pathophysiology and management. Clin J Am Soc Nephrol. 2006;1:1066–1079. doi:10.2215/CJN.01340406.
- Colle I, Durand F, Pessione F, et al. Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with Terlipressin: a retrospective analysis. J Gastroenterol Hepatol. 2002;17:882–888. CrossRef
- Watt K, Uhanova J, Minuk GY. Hepatorenal syndrome: diagnostic accuracy, clinical features, and outcome in a tertiary care center. Am J Gastroenterol. 2002;97:2046–2050. CrossRef
- Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology. 2004;40:55–64. CrossRef
- Peron J, Bureau C, Gonzalez L, et al. Treatment of hepatorenal syndrome as defined by the International Ascites Club by albumin and furosemide infusion according to the central venous pressure: a prospective pilot study. Am J Gastroenterol. 2005;100:2702–2707. CrossRef
- Platt JF, Ellis JH, Rubin JM, Merion RM, Lucey MR. Renal duplex Doppler ultrasonography: a noninvasive predictor of kidney dysfunction and hepatorenal failure in liver disease. Hepatology. 1994;20:362–369. CrossRef
- Lenz K. Hepatorenal syndrome: is it central hypovolemia, a cardiac disease, or part of gradually developing multiorgan dysfunction? Hepatology. 2005;42:263–265. CrossRef
- Skagen C, Einstein M, Lucey MR, Said A. Combination treatment with octreotide, midodrine and albumin improves survival in patients with type 1 and type 2 hepatorenal syndrome. J Clin Gastroenterol. 2009;43:680–685. CrossRef
- Keller F, Heinze H, Jochimsen F, Passfall J, Schuppan D, Buttner P. Risk factors and outcome of 107 patients with decompensated liver disease and acute renal failure (including 26 patients with hepatorenal syndrome): the role of hemodialysis. Ren Fail. 1995;17:135–146. CrossRef
- Capling RK, Bastani B. The clinical course of patients with type 1 hepatorenal syndrome maintained on hemodialysis. Ren Fail. 2004;26:563–568. CrossRef
- Appenrodt B, Zielinski J, Brensing KA, Heller J, Sauerbruch T, Schepke M. Degree of hepatic dysfunction and improvement of renal function predict survival in patients with HRS type I: a retrospective analysis. Eur J Gastroenterol Hepatol. 2009;21:1428–1432. CrossRef
- Witzke O, Baumann M, Patschan D, et al. Which patients benefit from hemodialysis therapy in hepatorenal syndrome? J Gastroenterol Hepatol. 2004;19:1369–1373. CrossRef
- Moreau R, Durand F, Poynard T, et al. Terlipressin in patients with cirrhosis and type I hepatorenal syndrome: a retrospective multicentric study. Gastroenterology. 2002;122:923–930. CrossRef
- Krag A, Møller S, Henriksen JH, Holstein-Rathlou NH, Larsen FS, Bendtsen F. Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome. Hepatology. 2007;46:1863–1871. CrossRef
- Hepatorenal Syndrome: Are We Missing Some Prognostic Factors?
Digestive Diseases and Sciences
Volume 57, Issue 1 , pp 210-214
- Cover Date
- Print ISSN
- Online ISSN
- Springer US
- Additional Links
- Hepatorenal syndrome
- Autoimmune hepatitis
- Industry Sectors
- Author Affiliations
- 2. Section of Gastroenterology and Hepatology, University of Nebraska Medical Center, 983040 Nebraska Medical Center, Omaha, NE, 69198-3040, USA
- 4. Department of Biostatistics, University of Nebraska Medical Center, 983040 Nebraska Medical Center, Omaha, NE, 69198-3040, USA
- 3. Section of Internal Medicine, University of Nebraska Medical Center, 983040 Nebraska Medical Center, Omaha, NE, 69198-3040, USA
- 1. Section of Nephrology, University of Nebraska Medical Center, 983040 Nebraska Medical Center, Omaha, NE, 69198-3040, USA